Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis

Annals of the Rheumatic Diseases

Volumn 64, Issue 8, 2005, Pages 1145-1149

  Vander Cruyssen, Bert ^a   Hoffman, I E A ^a   Zmierczak, H ^a   Van Den Berghe, M ^a   Kruithof, E ^a   De Rycke, L ^a   Mielants, H ^a   Veys, E M ^a   Baeten, D ^a   De Keyser, F ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; STATISTICAL ANALYSIS; X RAY FILM;

ADOLESCENT; ADULT; ARTHRITIS, PSORIATIC; AUTOANTIBODIES; AUTOANTIGENS; FEMALE; FOOT; HAND; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 23044441645     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.032177     Document Type: Article

References (33)

1. Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
2. Marsal S, Armadans-Gil L, Martinez M, Gallardo D, Ribera A, Lience E. Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology (Oxford) 1999;38:332-7.
3. Kane D, Stafford L, Bresniha'n B, FitzGerald O. A classification study of clinical subsets in an inception cohort of early psoriatic peripheral arthritis - "DIP or not DIP revisited". Rheumatology (Oxford) 2003;42:1469-76.
4. McGonagle D, Conaghan P, Emery P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 1999;42:1080-6.
5. Gladman D, Helliwell P, Mease PJ, Nash P, Titchlin C, Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004;50:24-35.
6. Veale D, Rogers S, FitzGerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994;33:133-8.
7. Fournie B, Crognier L, Arnaud C, Zabranieck L, Lascaux-Lefebvre V, Marc V, et al. Proposition de criteres de classification du rhumatisme psoriasique. Etude préliminaire de 260 patients. Rev Rhum (Ed Fr) 1999;66:513-24.
8. Taylor WJ, Helliwell PS. Development of diagnostic criteria for psoriatic arthritis: methods and process. Curr Rheum Rep 2004;6:299-305.
9. Koo T, Nagv Z, Sesztak M, Ujfalussy I, Meretey K, Bohm U, et al. Subsets in psoriatic arthritis formed by cluster analysis. Clin Rheumatol 2001;20:36-43.
10. Young BJJ, Mallya RK, Leslie RDG, Clarck CJM, Hamblin TJ. Anti-keratin antibodies in rheumatoid arthritis. BMJ 1979;2:97-9.
11. Girbal-Neuhauser E, Durieux J-J, Arnaud M, Dalbon P, Sebbag M, Vincent C, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999;162:585-94.
12. Schellekens GA, Visser H, de Jong BAW, van den Hoogen FHJ, Hazes JMW, Breedveld FC, Van Venrooij WJ. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
13. Pinheiro CG, Scheinberg MA, Aparecida da Silva M, Maciel S. Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med 2003;139:234-5.
14. Union A, Meheus L, Humbel RL, Conrad K, Steiner G, Moereels H, et al. Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum 2002;46:1185-95.
15. Hoffman IE, Peene I, Pottel H, Union A, Hulstaert F, Meheus L, et al. Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA shared epitope for diagnosis of rheumatoid arthritis. Clin Chem, 2004, Sep 23 [Epub ahead of print].
16. Vollbracht I, Rieber J, Oppermann M, Forger F, Siebert U, Helmke K. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004;63:1079-84.
17. Dubucquoi S, Solau-Servais E, Lefranc D, Marguerie L, Sibilia J, Goetz J, et al. Evaluation of anti-citrullinated fillagrin antibodies as hallmarks for the diagnosis of rheumatoid arthritis. Ann Rheum Dis 2004;63:415-19.
18. De Rycke L, Peene I, Hoffman I, Kruithof E, Union A, Meheus L, et al. Rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004;63:1587-93.
19. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003;62:870-4.
20. Suzuki K, Sawada T, Murakamani A, Matsui T, Tohma S, Nakazono K, et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 2003;32:197-204.
21. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondyloarthropathy Study Group: preliminary criteria for classification of Spondyloarthropathy. Arthritis Rheum 1991;34:1218-27.
22. Harper R, Reeves B. Reporting of precision of estimates for diagnostic accuracy: a review. BMJ 1999;318:1322-3.
23. Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, Van Venrooij WJ, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004;6:R303-8.
24. Palazzi C, Olivieri I, Petricca A, Salvarani C. Rheumatoid arthritis or psoritiatic symmetric polyarthritis? A difficult differential diagnosis. Clin Exp Rheumatol 2002;20:3-4.
25. Helliwell PS. Relationship of psoriatic arthritis with the other spondyloarthropathies. Curr Opin Rheumatol 2004;16:344-9.
26. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
27. Levin RW, Park J, Ostrov B, Reginato A, Baker DG, Bomalaski JS, Borofsky M, et al. Clinical assessment of the 1987 American College of Rheumatology criteria for rheumatoid arthritis. Scand J Rheumatol 1996;25:277-81.
28. Hoffman IEA, Peene I, Cebecauer L, Isenberg D, Huizinga T, Union A, et al. Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis 2005;64:330-2.
29. Mediwake R, Isenberg DA, Schellekens GA, van Venrooij WJ. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2001;60:67-68.
30. Gottenberg JE, Migot S, Nicaise-Rolland P, Cohen-Solal J, Aucouturier F, Goetz J, et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome. Ann Rheum Dis, 2004, Jul 1 [epub ahead of print].
31. Vossenaar ER, Van Boekel MA, van Venrooij WZ, Lopez-Hoyoz M, Merino J, Merino R, et al. Absence of citrulline-specific autoantibodies in animal models of autoimmunity. Arthritis Rheum 2004;50:2370-2.
32. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
33. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.